Literature DB >> 26591981

Continuous bladder irrigation in the monoplace hyperbaric chamber: Two case reports.

Jeffrey S Cooper, Peter Allinson, Dana Winn, Lon Keim, Joe Sippel, Patty Shalberg, Kari Fowler.   

Abstract

INTRODUCTION: Radiation-induced hemorrhagic cystitis is a serious side effect of radiation therapy. Anemia requiring transfusion can ensue. Treatment methods include bladder irrigation, fulguration, and hyperbaric oxygen (HBO2) therapy. Failure of treatment leads to cystectomy associated with a high risk of severe complications (42%) and mortality (16%). Continuous bladder irrigation (CBI) is often required to prevent further clot formation. HBO2 supports the healing process of radiation cystitis. In patients requiring CBI, the time in HBO2 can help cause clot accumulation and obstruction. We describe a method of providing CBI in a monoplace hyperbaric chamber.
MATERIALS AND METHODS: An IV to catheter adapter is used, allowing an IV pump to control CBI flow into the chamber. Drainage is collected in an extra-large (2- to 5-liter) bag. The rate is set so the volume does not exceed the bag's capacity. The bag is placed in a manner that precludes spilling and allows monitoring of outflow.
RESULTS: CBI was successfully maintained. Brief cases are presented and issues discussed. SUMMARY/
CONCLUSIONS: CBI is easily maintained in a monoplace hyperbaric chamber, with readily available equipment allowing for uninterrupted CBI of hemorrhagic cystitis. HBO2 helps mitigate the potential side effects of other interventions in a previously irradiated area.

Entities:  

Mesh:

Year:  2015        PMID: 26591981

Source DB:  PubMed          Journal:  Undersea Hyperb Med        ISSN: 1066-2936            Impact factor:   0.698


  1 in total

1.  Hyperbaric oxygen treatment for refractory haemorrhagic cystitis occurring after chemotherapy and haematopoietic stem cell transplantation: retrospective analysis of 25 patients.

Authors:  Handan Ozturk; Bengusu Mirasoglu; Samil Aktas
Journal:  Diving Hyperb Med       Date:  2022-03-31       Impact factor: 1.228

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.